 |
|
|
 |
Event Co-Chairs
Paul Jacobs |
Ted Torphy |
Edward Holmes |
Frieder Seible
Paul Jacobs, Ph.D.
Chief Executive Offi cer, QUALCOMM
Paul Jacobs, Ph.D., is chief executive offi cer of QUALCOMM Incorporated and is
also a member of the Company's board of directors. Dr. Jacobs has been the primary
driver of QUALCOMM's focus on enabling wireless data services, which make the cell
phone a tool not only for voice communications, but also the most personal device for
entertainment, computing and information access.
Following completion of his Ph.D. in 1989, and a year as a post-doctoral researcher
at a French government lab in Toulouse, Dr. Jacobs joined the company full-time
in 1990, as a development engineer leading the cell phone digital signal processor
software team. His early work focused on the initial variable-rate 8 kbps speech codec
for CDMA. Following this effort, Dr. Jacobs spearheaded the wireline-quality 13 kpbs
speech codec effort, which became CDMAs initial differentiating consumer feature. The
core engineering team involved in this effort would later be integral to the development
of QUALCOMM's LaunchpadT suite of multimedia functions that ship as software
with every QUALCOMM chipset. Known as an innovative leader of a broad range of
technical teams within QUALCOMM, Dr. Jacobs has also been granted more than 25
patents for his inventions in the area of wireless technology.
In 1995, he became vice president and general manager of the combined handset
and integrated circuit division, which was subsequently divided into QUALCOMM
Consumer Products (QCP) and QUALCOMM CDMA Technologies, respectively. He was
named senior vice president of the Company in 1996 and president of QCP in 1997;
he was named executive vice president of QUALCOMM in 2000 and group president
of QWI in 2001. QCP developed and manufactured the wireless industry's fi rst CDMA
digital handsets, supporting the rapid global deployment of cdmaOne in the 1990s.
Under Dr. Jacobs, that business became the number two CDMA handset supplier in
the U.S. prior to its sale to Kyocera Wireless in 2000, with revenues of more than $1.4
billion in QUALCOMM's Fiscal 1999. At QCP, Dr. Jacobs gained extensive operational
experience, helped launch numerous CDMA systems and cultivated important
executive relationships at top network operators and manufacturers globally.
Other, important developments which began under Dr. Jacobs in QCP include the
fi rst Palm OS®-based smartphone (now a rapidly growing category of mobile devices,
with third-party operating systems, offered by numerous manufacturers). He started
QUALCOMM's initiative to include global positioning system (GPS) capabilities in cell
phones. This led to the acquisition of SnapTrackT and QUALCOMM's development
of gpsOneT, and drove the development of a uniform set of application programming
interfaces (API), to simplify the process of putting software on handsets. Dr. Jacobs
expanded this latter idea into the overall concept for the BREW® system. The system
included dynamic downloading of applications to cellphones, with checks for digital
signatures on the applications, to ensure the integrity of the content, and the business
ecosystem that enables BREW developers to engage operators globally and receive
payment for their applications. The BREW solution is now deployed by more than 40
operators around the world.
back to top »
Ted Torphy, Ph.D.
Corporate Vice President, Corporate Offi ce of Science & Technology,
Johnson & Johnson
Dr. Ted Torphy joined the corporate staff of Johnson & Johnson in 2003 as Corporate
Vice President for Science and Technology. Ted heads the Corporate Offi ce of Science
and Technology (COSAT), which identifi es, evaluates and assimilates transformational
scientifi c, product and business opportunities across all of Johnson & Johnson business
sectors. COSAT also champions scientifi c excellence and facilitates collaboration among
Johnson & Johnson's exceedingly diverse R&D communities for the purpose of creating
new technology platforms and therapeutic approaches.
Dr. Torphy joined the corporate staff after spending three years at Centocor, where he
was Senior Vice President for Discovery and Preclinical Development. Prior to joining
Centocor, he spent 17 years with SmithKline Beecham, most recently as Vice President
of Research for the Cardiovascular, Pulmonary and Metabolic Diseases therapeutic areas.
Dr. Torphy is the author of more than 120 journal articles, review articles, book
chapters, and patents in the areas of molecular pharmacology, pulmonary therapeutics,
and drug discovery. He serves on the editorial advisory boards of eight scientifi c
journals, chairs the Board of Directors of the Cystic Fibrosis Therapeutics, Inc., and is a
board member of several other non-profi t organizations.
Dr. Torphy holds an undergraduate degree in Pharmacy from the University of
Wisconsin and a Ph.D. in Pharmacology and Toxicology from West Virginia University.
He completed his postdoctoral training at the University of California, San Diego.
back to top »
Edward Holmes, M.D.
Vice Chancellor for Health Sciences,Dean, UCSD School of Medicine
Edward Holmes, M.D. attended public secondary schools in Winona, Mississippi, received
a Bachelor of Science degree from Washington and Lee University, and received a Doctor
of Medicine degree from the University of Pennsylvania. He pursued internal medicine
training at the Hospital of the University of Pennsylvania and Duke University Medical
Center, serving as Chief Medical Resident at the latter institution. Following research
fellowship training in the USPHS and at Duke University Medical School, he joined
the faculty at Duke University School of Medicine in 1974 as an Assistant Professor of
Medicine and Biochemistry. Dr. Holmes was also appointed as a Howard Hughes Medical
Investigator (HHMI) at Duke University and remained in HHMI for 13 years. He rose
through the ranks to become the Chief of the Division of Endocrinology, Metabolism and
Genetics and the James B. Wyngaarden Professor of Medicine at Duke University. Dr.
Holmes was recruited to the University of Pennsylvania School of Medicine in 1991 to
become the Chair of the Department of Medicine and the Frank Wister Thomas Professor
of Medicine and Genetics. In 1997 he moved to Stanford University School of Medicine
to become the Joseph Grant Professor in the School of Medicine, the Senior Associate
Dean for Research, Vice President for Translational Medicine and Clinical Research, and
Special Counselor to the President of the University on Biomedical Research. In January
1999, Dr. Homes returned to Duke University as the Dean of the School of Medicine,
Vice Chancellor for Academic Affairs and the Walter Kempner Professor of Medicine
and Genetics. Dr. Holmes was appointed the Vice Chancellor for Health Sciences and
Dean to the School of Medicine at the University of California, San Diego in the fall of
2000. Dr. Holmes has engaged in basic biomedical and clinical research throughout his
academic career, holding continuous National Institute of Health (NIH) funding since
1975, including a MERIT Award. His laboratory has made signifi cant contributions to our
understanding of the control of purine biosynthesis. After cloning the fi rst member of the
AMP deaminase multigene family; his group has pioneered a multinational effort to defi ne
the role of these genes in health and disease. Dr. Holmes has also been a national leader
in developing innovative programs for training and sustaining physician scientists in
academic medical centers. He has served on numerous university, industrial and national
advisory boards. He is currently active on the NIH Scientifi c Boundaries Panel, the
Scientifi c Advisory Board of SmithKline Beecham, and the National Diabetes and Digestive
and Kidney Diseases Advisory Council of the NIH. He has been elected to membership in
the American Society for Clinical Investigation, the Association of American Physicians, a
Fellow of the American Association for the Advancement of Science, and a member of the
Institute of Medicine of the National Academy of Sciences.
back to top »
Frieder Seible, Ph.D.
Dean, UCSD Jacobs School of Engineering, Professor, Structural Engineering
Frieder Seible, Ph.D. is the Dean of the UCSD Jacobs School of Engineering and holds
the Eric and Johanna Reissner Chair in Applied Mechanics and Structural Engineering.
He developed and directs the Charles Lee Powell Structural Research Laboratories, which
serve as a worldwide resource for full-scale testing and analysis of structures. Seible is a
member of the National Academy of Engineering, and a recipient of the CERF Charles
Pankow Award for Innovation. He has served on or led many Caltrans committees on
bridge reconstruction and retrofi t. Seible has published more than 500 papers and
technical reports mainly related to seismic design of bridges and buildings. Seible received
a Dpl. Ing. from the University of Stuttgart, a M.Sc. from the University of Calgary, and a
Ph.D. from the University of California, Berkeley, all in civil engineering. Before joining
UCSD, Seible was a design engineer at Philipp Holzmann AG in Frankfurt, Germany.
back to top »
|
|
